Clinical validation study update

LungLife AI, INC

28 September 2023

 

LungLife AI, Inc.
(the "Company" or "LungLife")

Clinical validation study update

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company's clinical validation study for its LungLB® test.

As stated in the Company's half-year report on 8 August 2023, LungLife is currently focussed on preparing data from the clinical validation study for detailed analysis, which was expected to be concluded by the end of September 2023. Due to delays in the provision of data from study sites, full database lock, and the consequent knock-on impact on ability to analyse the data we now expect this to be concluded in Q4 2023.

For further information please contact:

LungLife AI, Inc.	www.lunglifeai.com
Paul Pagano, CEO	Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser & Joint Broker)	Tel: [phone]
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
Goodbody (Joint Broker) Tom Nicholson / Stephen Kane	Tel: [phone]
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings / Phillip Marriage	Mob: [phone]

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

 

END